EUCTR2019-001562-15-NL进行中（未招募）1 期
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET - NETTER-2
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 222
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Presence of metastasized or locally advanced, inoperable (curative intent) histologically proven, well differentiated Grade 2 or Grade 3 gastroenteropancreatic neuroendocrine (GEP-NET) tumor diagnosed within 6 months prior to screening.
- •2. Ki67 index =10 and = 55%.
- •3. Patients =15 years of age and a body weight of >40 kg at screening.
- •4. Expression of somatostatin receptors on all target lesions documented by CT/MRI scans, assessed by any of the following somatostatin receptor imaging (SRI) modalities within 3 months prior to randomization: [68Ga]-DOTA-TOC (e.g. Somakit-TOC®) PET/CT (or MRI when applicable based on target lesions) imaging, [68Ga]-DOTA-TATE PET/CT (or MRI when applicable based on target lesions) imaging (e.g. NETSPOT®), Somatostatin Receptor scintigraphy (SRS) with [111In]-pentetreotide (Octreoscan® SPECT/CT), SRS with [99mTc]-Tektrotyd, [64Cu]-DOTA-TATE PET/CT (or MRI when applicable based on target lesions).
- •5. The tumor uptake observed in the target lesions must be > normal liver uptake.
- •6. Karnofsky Performance Score (KPS) =60.
- •7. Presence of at least 1 measurable site of disease.
- •8. Patients who have provided a signed informed consent form to participate in the study, obtained prior to the start of any protocol related activities.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 112
排除标准
- •1. Creatinine clearance <40 mL/min calculated by the Cockroft Gault method.
- •2. Hb concentration <5.0 mmol/L (<8.0 g/dL); WBC <2x10^9/L (2000/mm^3); platelets <75x10^9/L (75x10^3/mm^3).
- •3. Total bilirubin >3 x ULN.
- •4. Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.
- •5. Pregnancy or lactation.
- •6. A) Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, are not allowed to participate in this study UNLESS they are using highly effective methods of contraception throughout the study treatment period (including cross-over and re-treatment, if applicable) and for 6 months after study drug discontinuation.
- •B) Sexually active male patients, unless they agree to remain abstinent (refrain from heterosexual intercourse) or be willing to use effective methods of contraception with female partners of childbearing potential or pregnant female partners during the treatment period (including cross-over and re-treatment, if applicable) and for 6 months after study drug discontinuation. In addition, male patients must refrain from donating sperm during this same period.
- •7. Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization in the study.
- •8. Documented RECIST progression to previous treatments for the current GEP-NET at any time prior to randomization.
- •9. Patients for whom in the opinion of the investigator other therapeutic options (eg chemo-, targeted therapy) are considered more appropriate than the therapy offered in the study, based on patient and disease characteristics.
- •10. Any previous therapy with Interferons, Everolimus (mTOR-inhibitors), chemotherapy or other systemic therapies of GEP-NET administered for more than 1 month or within 12 weeks prior to randomization in the study.
- •11. Any previous radioembolization, chemoembolization and radiofrequency ablation for GEP-NET.
- •12. Any surgery within 12 weeks prior to randomization in the study.
- •13. Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to screening in the study. Patients with a history of brain metastases must have a head CT or MRI with contrast to document stable disease prior to randomization in the study.
- •14. Uncontrolled congestive heart failure (NYHA II, III, IV). Patients with history of congestive heart failure who do not violate this exclusion criterion will undergo an evaluation of their cardiac ejection fraction prior to randomization via echocardiography. The results from an earlier assessment (not exceeding 30 days prior to randomization) may substitute the evaluation at the discretion of the Investigator, if no clinical worsening is noted. The patient’s measured cardiac ejection fraction in these patients must be >40% before randomization.
- •15. QTcF > 470 msec for females and QTcF > 450 msec for males or congenital long QT syndrome.
- •16. Uncontrolled diabetes mellitus as defined by hemoglobin A1c value > 7.5%.
- •17. Hyperkaleamia >6.0 mmol/L (CTCAE Grade 3) which is not corrected prior to study enrolment.
- •18. Any patient receiving treatment with short-acting octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutathera, or any patient receiving treatment with SSAs (eg octreotide long-acting), which cannot be interrupted for at least 6 weeks before the administration of Lutathera.
- •19. Patients with any other significant medical, psychiatric, or surgical con
研究者
相似试验
招募中
1 期
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive care octreotide long-acting (30 mg), when given as a 1st line treatment in GEPNET patients with high proliferation rate tumors (G2 and G3), in comparison to treatment with high dose (60 mg) octreotide long-actingPatients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETsMedDRA version: 20.0Level: LLTClassification code: 10077560Term: Gastroenteropancreatic neuroendocrine tumor disease Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10077559Term: Gastroenteropancreatic neuroendocrine tumour disease Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10052399Term: Neuroendocrine tumour Class: 100000004864CTIS2023-507443-10-00Advanced Accelerator Applications222
进行中（未招募）
1 期
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive care octreotide long-acting (30 mg), when given as a 1st line treatment in GEP-NET patients with high proliferation rate tumors (G2 and G3), in comparison to treatment with high dose (60 mg) octreotide long-acting.EUCTR2019-001562-15-DEAdvanced Accelerator Applications222
招募中
3 期
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NETGEP-NETs (gastro-entero-pancreatic neuroendocrine tumors)including the stomachintestinespancreas and liver.progressive malignant tumors that can occur in various organs1005254710014713NL-OMON55150Advanced Accelerator Applications Internationals SA10
进行中（未招募）
不适用
A phase III randomized, open-label, multi-center study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have suboptimal cytogenetic response (CyR) on imatinib - NDChronic Myelogenous Leukemia (CML) Ph+ chronic phaseMedDRA version: 6.1Level: PTClassification code 10009013EUCTR2005-005047-26-ITOVARTIS FARMA608
进行中（未招募）
不适用
A phase III randomized, open-label, multi-center study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have suboptimal cytogenetic response (CyR) on imatinib.EUCTR2005-005047-26-DEovartis Pharma Services AG608